Renin-Angiotensin-Aldosterone Inhibitors and COVID-19

• There is a concern that renin–angiotensin–aldosterone system (RAAS) blockers increase susceptibility to coronavirus 2019 (COVID-19). • There no evidence that treatment with RAAS blockers worsens the course of COVID-19. • Discontinuation of RAAS blockers may exacerbate cardiovascular comorbidities....

Descripción completa

Detalles Bibliográficos
Autores principales: Benenson, Irina, Waldron, Frederick Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237918/
https://www.ncbi.nlm.nih.gov/pubmed/32834792
http://dx.doi.org/10.1016/j.nurpra.2020.05.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237918/
https://www.ncbi.nlm.nih.gov/pubmed/32834792
http://dx.doi.org/10.1016/j.nurpra.2020.05.007

Ejemplares similares